📌 Key Takeaways
- The question in advanced filler practice is no longer
“how much to inject” — it’s
“how to read the face before you inject.” - Natural-looking results depend not on volume,
but on understanding facial structure, movement,
and layered anatomy. - Rheology metrics — G’ (elastic modulus) and strain —
reframe “soft vs. firm” into a science-based
clinical decision framework. - NASHA® and OBT™ are not ranked by quality;
they represent different roles:
positional retention vs. dynamic conformity. - The AART framework (Assessment → Anatomy → Range → Treatment)
offers a structured way to read the face
as a spatial whole, not a collection of parts.
When most people think about hyaluronic acid (HA) filler treatments,
the conversation tends to center on two questions:
Which product? and How much?
But at a recent closed-door physician session focused on Restylane®,
the discussion among clinicians from Hong Kong and Japan
was centered on something entirely different:
what to observe — and how to think — before a single injection is made.
An international plastic surgeon presented a framework for reading the face
as a spatial blueprint rather than a set of isolated features.
A Japanese clinician introduced rheology —
the science of material deformation and flow —
as a tool to replace intuition-based product selection
with reproducible, physics-grounded judgment.
And throughout the panel discussion, one phrase kept surfacing:
not “how much to change,” but “where to stop.”
This was a closed, physician-only event.
Photography was permitted in limited areas only.
Images in this article reflect the session environment,
not specific clinical content.
Opening: Why Do Some Filler Results Look Natural — and Others Don’t?
The sessions did not focus on new techniques or trending products.
The central question was:
how do you observe a face, and how far should you intervene?
Facial assessment methodology, rheological science,
and product selection based on physical properties —
each topic was distinct, but all pointed to the same underlying principle:
“How well do you understand the face before you treat it?”
What emerged across the day was a sense that HA filler practice
is shifting — from a conversation about volume
to a discipline of understanding why natural results happen.
Session 1: Introduction to AART and Deep Dive into Facial Assessment
This session involved advanced clinical judgment for physician audiences.
Specific injection techniques and case details are not covered in this article.
Reading the Face as Space, Not Parts: The AART Framework
SPEAKER | Dr. Stephanie Lam
Central Health Medical Practice, Hong Kong — Plastic Surgeon
When patients seek filler treatment, they typically arrive focused on one area:
nasolabial folds, under-eye hollows, lip volume.
Dr. Stephanie Lam’s opening move was to gently challenge that framing.
Addressing a single concern in isolation, she argued,
can produce results that feel off —
even when the targeted area itself looks improved —
because the overall facial balance remains unchanged.
The more productive starting point, she proposed,
is to observe the face not as a collection of parts,
but as a spatial composition —
before any treatment plan is formed.
The AART Evaluation Sequence
The framework Dr. Lam introduced is called AART:
Rather than moving directly to injection,
AART asks the clinician to first map the face systematically:
skin quality, skeletal structure, volume distribution,
asymmetry, and habitual expression patterns.
One of the session’s most striking observations:
the same HA product, placed in a different layer,
can produce dramatically different outcomes.
Because aging affects bone, fat compartments, muscle, and skin simultaneously,
understanding which layer has changed matters more
than simply deciding where to inject.
The Case for Staged Treatment
Dr. Lam also introduced the concept of staged intervention —
resisting the impulse to address everything at once.
In some cases, treating an area the patient didn’t initially request
can produce a more harmonious overall result
than targeting the chief complaint directly.
This approach, she noted, allows patients to experience
gradual, comprehensible change —
rather than a sudden transformation that may feel unfamiliar.
A recurring theme in the lecture:
facial assessment is not only a diagnostic tool.
It functions as a communication framework —
helping patients understand their own facial changes
and build informed expectations around treatment.
Natural results are shaped by how you read the face — not by how much you inject.
✅ Where the patient wants treatment ≠ where treatment should begin
· AART provides a sequential thinking structure for facial evaluation
· Layer placement matters as much as product choice
· Staged treatment supports natural-looking, patient-understood outcomes
· Facial assessment doubles as a patient communication tool
Session 2: Understanding Rheology — Choosing Products by Science, Not Sensation
This session involved advanced injection judgment.
Specific techniques and case details are not covered here.
Is “Feels Soft” a Good Enough Reason to Choose a Filler?
SPEAKER | Dr. Naruaki Miyata
Director, Miyata Plastic Surgery & Dermatology Clinic, Japan
Hyaluronic acid fillers have long been described in sensory terms:
“firm,” “blendable,” “natural-feeling.”
Dr. Miyata’s opening question cut through that language directly:
“Can you reproduce that result reliably —
or was it a fortunate accident?”
To move treatment outcomes from chance to consistency,
he argued, clinicians need a scientific understanding
of how filler materials actually behave.
That’s where rheology enters the picture.
Rheology is the study of how materials deform and flow
when force is applied — a branch of physics
applied here to injectable biomaterials.
G’, G”, and Strain: What the Numbers Actually Mean
relates to a product’s ability to maintain shape
energy dissipated during dynamic deformation
before structural breakdown
Dr. Miyata’s core argument:
HA fillers should not be understood simply as “hard” or “soft.”
What matters clinically is how they behave when the face moves.
The face is not a static structure.
Smiling, speaking, tensing —
each of these actions generates significant internal forces.
In that context, the relevant question is not
“how firm is this product?”
but rather: how much deformation can it tolerate before it fails?
This is why strain — not G’ alone —
becomes a critical variable in clinical product selection.
“Filler Face” Is a Design Problem, Not a Product Problem
The latter half of the lecture used everyday materials —
toothpaste, mayonnaise — to illustrate how substances
change behavior depending on the type and magnitude of force applied.
HA fillers behave similarly.
Some are designed for structural support and positional retention.
Others are designed to conform to movement.
The proposed design principle:
balance G’ against strain tolerance —
selecting not the “best” product by spec,
but the most appropriate product for the specific facial zone and movement pattern.
The line that stayed with the room:
“Filler face is not caused by the product.
It’s caused by judgment that lacks scientific grounding.”
Social media impressions and tactile intuition are not sufficient foundations
for clinical decision-making.
Understanding material properties is what separates
aesthetic injection from aesthetic medicine.
During this session, NASHA® and OBT™ were referenced as examples
of how different manufacturing processes produce different rheological profiles —
one optimized for structural support, the other for dynamic conformity.
The discussion was not a comparative ranking of products.
It was a framework for understanding material behavior
in the context of clinical design.
Natural results are determined by rheological understanding — not by softness alone.
✅ HA fillers cannot be evaluated by firmness perception alone
· G’ × strain balance is the relevant clinical metric
· The face is a dynamic environment — static hardness is insufficient
· Elastic support and dynamic conformity serve different clinical roles
· Science-based selection is the foundation of reproducible outcomes
Session 3: Optimal Balance Technology — Matching Product Properties to Facial Movement
This session involved advanced injection judgment.
Specific techniques and case details are not covered here.
Neither “Firmer Is Better” Nor “Softer Is More Natural”
SPEAKER | Dr. Stephanie Lam
Central Health Medical Practice, Hong Kong — Plastic Surgeon
Filler products have historically been described in binary terms:
“lifting” vs. “blendable,” “structural” vs. “natural.”
Dr. Lam’s third session challenged that binary directly —
not by proposing a better product,
but by reframing the question itself.
The comparison between NASHA® and OBT™ was not presented as a competition.
It was a lens for understanding how product properties relate to facial movement.
NASHA® was described through the concept of
Targeted Product Integration —
a tendency to remain at the site of injection,
supporting structural projection and positional stability.
OBT™ was introduced through the concept of
Distributed Product Integration —
a tendency to spread and conform to surrounding tissue,
adapting to dynamic facial zones.
The key distinction is not superiority.
It is which movement pattern requires which property.
Naturalness Is Evaluated When the Face Moves — Not When It’s Still
From a rheological perspective, the session distinguished between:
· Structurally supportive products — for projection and volume retention
· High-flexibility products — for areas with significant expression movement
NASHA® was discussed in the context of
three-dimensional structural support and lift.
OBT™ was introduced as appropriate for
dynamic zones and areas with high expression variability.
The phrase that defined the session:
“Naturalness is not evaluated at rest.
It’s evaluated the moment the face moves.”
The face is always in motion —
smiling, speaking, tensing, relaxing.
Each movement changes the internal environment.
The clinical question, therefore, is not
“how well can this product build shape?”
but “how well does it conform to movement?”
The latter part of the session introduced OBT™’s design philosophy:
Firmness × Flexibility —
a balance concept that positions high strain tolerance
as the mechanism behind what the brand calls “Perfect Balance.”
Throughout the lecture, one message was consistently reinforced:
the product is a tool within a clinical design system —
not the design itself.
Clinical examples touched on:
· Volumetric shaping in tissue-dense areas
· Lower face zones with high movement amplitude
· Subtle perioral and chin refinement
In each case, the emphasis was on
matching material properties to structural and dynamic context —
not on defaulting to a single preferred product.
“Natural” is defined by dynamic conformity — not by firmness.
✅ NASHA® and OBT™ represent different roles, not a quality hierarchy
· NASHA® = positional retention and structural support
· OBT™ = dynamic conformity and flexibility
· Product selection must account for expression movement
· Firmness × Flexibility is a new evaluative axis for clinical design
Conclusion: From “How Much to Inject” to “How to Read the Face”
What ran through every session was not a new product or a new technique.
It was a shift in the underlying question that drives clinical judgment.
HA filler practice appears to be moving —
gradually but clearly —
from “which product, how much”
to “how do I read this face before I treat it?”
Dr. Lam’s AART framework offered a structured way
to perceive the face as a spatial whole —
not a list of complaints to address sequentially.
Dr. Miyata’s rheology session replaced sensory vocabulary
with measurable parameters — G’, G”, and strain —
giving clinicians a physics-based language
for product selection and outcome prediction.
And the Optimal Balance Technology discussion reframed
NASHA® vs. OBT™ not as a competition,
but as a vocabulary of role differentiation:
positional retention vs. dynamic conformity,
each serving a different clinical purpose.
The panel discussion — featuring Dr. Tomoko Keida,
Dr. Akiko Tanaka, and Dr. Atsuko Yanagawa —
brought these frameworks into daily clinical reality.
Drawing on long-term follow-up and real-world practice patterns,
they discussed the limits of intervention
and the design logic behind knowing when to stop.
Three observations from the panel stood out:
· Small volumes can produce significant perceptual change
when placement is precise
· Understanding material properties makes it easier
to decide when not to add more
· The goal is not to erase — it is to design for naturalness
What the day ultimately pointed toward was not technical virtuosity.
It was the discipline of knowing where to stop —
and the clinical intelligence required to get there.
- AART (Assessment → Anatomy → Range → Treatment)
provides a structured pre-treatment evaluation sequence
that reads the face as a spatial whole - Rheological parameters — G’, G”, and strain —
offer a science-based alternative to sensory product selection - NASHA® and OBT™ represent different design philosophies:
positional retention vs. dynamic conformity - “Filler face” is a design problem, not a product problem —
it results from judgment without scientific grounding - The emerging standard in advanced filler practice:
read the face first, design the intervention second
It is a sequential evaluation framework that asks clinicians
to fully assess facial structure — including bone, fat, muscle, and skin layers —
before forming a treatment plan.
Rather than addressing the patient’s chief complaint directly,
AART encourages reading the face as a spatial whole
to achieve more balanced, natural-looking outcomes.
Applied to HA fillers, it means evaluating products not just by firmness,
but by parameters like G’ (elastic modulus, shape retention),
G” (viscous loss during movement), and strain (deformation tolerance).
Because the face is a dynamic environment —
constantly moving through expression —
these metrics provide a more clinically relevant basis
for product selection than tactile impression alone.
are two different manufacturing technologies used in Restylane products.
NASHA® is associated with Targeted Product Integration —
staying at the injection site to provide structural support and projection.
OBT™ is associated with Distributed Product Integration —
conforming to surrounding tissue and adapting to dynamic facial movement.
They are not ranked by quality;
they serve different clinical roles depending on the treatment zone.
Source: Physician-only closed session on Restylane® (Galderma), Japan, February 2026.
Speakers: Dr. Stephanie Lam (Central Health Medical Practice, Hong Kong);
Dr. Naruaki Miyata (Miyata Plastic Surgery & Dermatology Clinic, Japan).
Panel: Dr. Tomoko Keida, Dr. Akiko Tanaka, Dr. Atsuko Yanagawa.
NERO editorial team attended as independent press observers.
No commercial relationship with Galderma or any product manufacturer
influenced the editorial content of this article.
